skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Preoperative determination of reversibility of wall motion abnormalities using F-18 fluorodeoxyglucose and N-13 ammonia positron tomography

Conference · · J. Nucl. Med.; (United States)
OSTI ID:6861793

The authors postulated that positron emission tomography (PET) with F-18 fluorodeoxyglucose (FDG) and N-13 ammonia (NH3) performed preoperatively could predict recovery of segmental ventricular function following revascularization in patients with ischemic heart disease and resting wall motion abnormalities. The ventricle was divided into anterior, lateral, inferoposterior and septal regions and wall motion abnormalities were determined in blind fashion from angiogram, radionuclide ventriculogram and 2-D echo. Using criteria previously established in this lab, regional infarction was defined as reduction in both NH3 and FDG counts, while ischemia was identified by an increase in FDG counts relative to NH3 counts. Infarcted regions were expected to show little or no improvement in wall motion while normal or ischemi regions were expected to show improved function following revascularization. Abnormal wall motion was identified in 28 regions in 12 patients; in 10 of these patients (13 regions) there was evidence clinically of prior transmural infarction. Of the 15 regions which were either ischemic or normal tomographically, 14 had improved function postoperatively, including 5 with clinical evidence of prior infarction. Of the 13 regions classified as infarct, none showed improved function postoperatively including 8 with no prior clinical evidence of infarct. Thus, PET with FDG and NH3 can reliably predict recovery of segmental function following revascularization in patients with resting wall motion abnormalities.

Research Organization:
UCLA Center for the Health Sciences, Los Angeles, CA
OSTI ID:
6861793
Report Number(s):
CONF-840619-; TRN: 87-018916
Journal Information:
J. Nucl. Med.; (United States), Vol. 25:5; Conference: 31. annual meeting of the Society of Nuclear Medicine, Los Angeles, CA, USA, 5 Jun 1984
Country of Publication:
United States
Language:
English